Tauriga Sciences, Inc. Initiates Clinical Trial to Examine the Effects of Cannabidiol Doses on Pregnant Women with Diagnosis of Hyperemesis Gravidarum
08/31/2021 - 08:00 AM
The Company’s Proposed Cannabidiol Delivery System Utilizes its Proprietary Cannabidiol (“CBD”) Infused Chewing Gum Platform
NEW YORK, NY, Aug. 31, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire
This planned Clinical Trial will launch the Company’s pharmaceutical development initiative and will secure Tauriga Sciences Inc. as the only Company evaluating Cannabidiol in this specific patient population.
The Company’s proposed Cannabidiol delivery system, utilizes its proprietary Cannabidiol infused chewing gum platform. This focuses on Sublingual Delivery, which refers to the pharmacological route of administration by which substances diffuse into the blood through tissues under the tongue. The Company expects to develop “mission critical” versions of its proprietary chewing gum, incorporating varying concentrations of CBD (potentially combined with other substances).
The Company is currently in the process of finalizing the study protocol, to be submitted, reviewed, and approved by a central Institutional Review Board (“IRB”). The Company’s efforts, with respect to this corporative initiative, are being spearheaded by its Chief Medical Officer – Dr. Keith Aqua.
Tauriga’s Chief Medical Officer, Dr. Keith Aqua, commented, “Nausea and vomiting in early pregnancy are both significant physical and psychological health risks. Pregnant women frequently ingest multiple medications for which there is little data on the effectiveness and safety for both themselves or their developing fetuses. Roughly 5% of pregnant women consume some form of cannabinoid, the two most common being CBD and THC. Unlike alcohol, to date, no known syndrome or specific birth defect has been identified to be caused by these products. Despite being considered a vulnerable population, pregnant women have few clinical trials presenting rigorous scientific data to understand how these molecules interact with the mother and fetus. We intend to add to the fund of knowledge regarding the effects of CBD on pregnant women by performing this and other scientific clinical trials.”
This Corporate Initiative, is in addition to its ongoing Pharmaceutical development efforts – Targeting: Patients Subjected to Ongoing Chemotherapy Treatment. This relates to the development of its previously disclosed, Cannabinoid based, Pharmaceutical grade version of Tauri-Gum™ -- for nausea regulation.
ABOUT TAURIGA SCIENCES INC.
Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol (“CBD”) and Cannabigerol (“CBG”) Edibles market segment. The main product line, branded as Tauri-Gum™, consists of a proprietary supplement chewing gum that is Kosher certified, Halal certified, and Vegan Formulated (CBD Infused Tauri-Gum™ Flavors: Mint, Blood Orange, Pomegranate), (CBG Infused Tauri-Gum™ Flavors: Peach-Lemon, Black Currant), (DELTA 8 THC Infused Tauri-Gum™ Flavor: Evergreen Mint), (Vitamin C + Zinc Infused Tauri-Gum™ Flavor: Pear Bellini), (Caffeine Infused Tauri-Gum™ Flavor: Cherry Lime Rickey), & (Vitamin D3 Infused Tauri-Gum™ Flavor: Golden Raspberry). The Company’s commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at http://www.tauriga.com
Complementary to the Company’s retail business, is its ongoing Pharmaceutical Development initiative. This relates to the development of a proposed Pharmaceutical grade version of Tauri-Gum™, for nausea regulation (specifically designed for the following indication: Patients Subjected to Ongoing Chemotherapy Treatment). On March 22, 2021, the Company announced that it had Converted its U.S. Provisional Patent Application (filed on March 17, 2020) into a U.S. Non-Provisional Patent Application. The Patent, filed with the U.S.P.T.O. is Titled “MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT”. On December 18, 2020 the Company disclosed that it had entered into a Master Services Agreement with CSTI to lead the Company's clinical development efforts.
The Company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full time E-Commerce fulfillment centers: one located in Montgomery, Texas and the other in Brooklyn, New York.
DISCLAIMER -- Forward-Looking Statements
This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.
Contact:
Tauriga Sciences, Inc.www.tauriga.com www.taurigum.com
